BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 20216317)

  • 1. Update on chemoprevention for prostate cancer.
    Strope SA; Andriole GL
    Curr Opin Urol; 2010 May; 20(3):194-7. PubMed ID: 20216317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on prostate cancer chemoprevention.
    Lowe JF; Frazee LA
    Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of prostate cancer.
    Stephenson AJ; Abouassaly R; Klein EA
    Urol Clin North Am; 2010 Feb; 37(1):11-21, Table of Contents. PubMed ID: 20152515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer: a serious disease suitable for prevention.
    Fitzpatrick JM; Schulman C; Zlotta AR; Schröder FH
    BJU Int; 2009 Apr; 103(7):864-70. PubMed ID: 19302133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of pivotal studies for prostate cancer risk reduction, past and present.
    Andriole GL
    Urology; 2009 May; 73(5 Suppl):S36-43. PubMed ID: 19375625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of prostate cancer.
    Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Klein EA
    J Urol; 2009 Aug; 182(2):499-507; discussion 508. PubMed ID: 19524966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can prostate cancer be prevented?
    Klein EA
    Nat Clin Pract Urol; 2005 Jan; 2(1):24-31. PubMed ID: 16474573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB; Parekh DJ
    Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
    Goetzl MA; Holzbeierlein JM
    Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.
    Crawford ED; Andriole GL; Marberger M; Rittmaster RS
    Urology; 2010 Mar; 75(3):502-9. PubMed ID: 20035983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on chemoprevention strategies in prostate cancer for 2006.
    Neill MG; Fleshner NE
    Curr Opin Urol; 2006 May; 16(3):132-7. PubMed ID: 16679848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of phase III clinical trials of prostate cancer chemoprevention.
    Thorpe JF; Jain S; Marczylo TH; Gescher AJ; Steward WP; Mellon JK
    Ann R Coll Surg Engl; 2007 Apr; 89(3):207-11. PubMed ID: 17394699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M; Fleshner NE; Finelli A; Zlotta AR
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgens and prevention of prostate cancer.
    Sarvis JA; Thompson IM
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):271-7. PubMed ID: 18438176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
    Mellon JK
    Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost of prostate cancer chemoprevention: a decision analysis model.
    Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention.
    Canby-Hagino E; Hernandez J; Brand TC; Thompson I
    Eur Urol; 2007 Jan; 51(1):27-33. PubMed ID: 17030406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.